Pérez R, Pravia R, Linares A, González M, Rodríguez M, Lombraña J L, Riestra S, Suárez A, Rodrigo L
Gastroenterology Unit, Hospital Central de Asturias, School of Medicine, Oviedo, Spain.
Gut. 1993;34(2 Suppl):S136-8. doi: 10.1136/gut.34.2_suppl.s136.
This randomised, controlled trial was designed to assess the response to a nine month course of interferon (IFN) alfa-2b, starting with a higher than usual dose. Forty eight patients received IFN 5 million units (MU) three times a week for eight weeks followed by 3 MU three times weekly for seven months; 25 patients in the control group received no treatment. The overall response to treatment was 68.7%, an improvement over other studies, but the high rate of relapse (85% in patients who responded) suggested that a nine month treatment period was insufficient in most cases. Histological improvement was seen in more than 80% of responders to interferon, including a reduction in inflammatory activity, necrosis, and fibrosis.
这项随机对照试验旨在评估从高于常规剂量开始的为期九个月的干扰素（IFN）α-2b疗程的疗效。48名患者接受每周三次、每次500万单位（MU）的干扰素治疗，持续8周，随后每周三次、每次300万单位，持续7个月；25名对照组患者未接受治疗。治疗的总体有效率为68.7%，高于其他研究，但高复发率（有反应患者中的85%）表明，在大多数情况下，九个月的治疗期并不足够。超过80%的干扰素反应者出现了组织学改善，包括炎症活动、坏死和纤维化的减轻。
